Case-Based Roundtable Meetings Spotlight: February 1, 2022

Roundtable Discussion: Dowlati Debates the Role of Osimertinib in Adjuvant Treatment of NSCLC

February 03, 2022

Clinical Articles

During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, and participants discussed the challenges of molecular testing and how to use test results to introduce targeted treatments for patients with non–small cell lung cancer.

Roundtable Discussion: Aghalar and Vaena Look at The role of Cabazitaxel in CRPC

February 01, 2022

Clinical Articles

During a Targeted Oncology live event, Jahan Aghalar, MD, and Daniel Vaena, MD, discussed the results of trials of cabazitaxel in patients with castration-resistant prostate cancer and how to manage toxicity of the therapy.

Lunning Discusses Second-Line Treatments in Diffuse Large B-Cell Lymphoma

January 31, 2022

Clinical Articles

During a Targeted Oncology case-based roundtable event, Matthew A. Lunning, DO, discussed the results of the L-MIND study of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma.

Gadgeel Discusses Therapies for Patients With NSCLC and CNS Metastases

January 29, 2022

Clinical Articles

During a Targeted Oncology case-based roundtable event, Shirish M Gadgeel, MD, discussed the results of the ALEX, ALTA-1L, and CROWN studies of immune checkpoint inhibitors in non–squamous non–small cell lung cancer.

Roundtable Discussion: Integrating New Approaches for Advanced Relapsed/Refractory RCC Into Practice

January 28, 2022

Clinical Articles

During a Targeted Oncology case-based roundtable event, Sumanta Kumar Pal, David I. Quinn, MD, MBBS, PhD, and participants discussed frontline therapy options for a patient with metastatic relapsed/refractory renal cell carcinoma.